Featured Research

from universities, journals, and other organizations

Study evaluates intranasal insulin therapy for adults with mild cognitive impairment or Alzheimer’s

Date:
September 13, 2011
Source:
JAMA and Archives Journals
Summary:
Intranasal insulin therapy appears to provide some benefit for cognitive function in patients with amnestic mild cognitive impairment and Alzheimer disease, according to a new study.

Intranasal insulin therapy appears to provide some benefit for cognitive function in patients with amnestic mild cognitive impairment and Alzheimer disease, according to a report published Online First by Archives of Neurology, one of the JAMA/Archives journals.

According to background information in the article, insulin plays a role in a number of functions of the central nervous system. "The importance of insulin in normal brain function is underscored by evidence that insulin dysregulation contributes to the pathophysiology of Alzheimer disease (AD), a disorder characterized in its earliest stages by synaptic loss and memory impairment," the authors write. "Insulin levels and insulin activity in the central nervous system are reduced in AD."

Suzanne Craft, Ph.D., of the Veterans Affairs Puget Sound Health Care System and the University of Washington School of Medicine, Seattle, and colleagues conducted a randomized controlled trial to evaluate the effects of intranasal insulin therapy on cognition, function, cerebral glucose metabolism and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive impairment (aMCI) or AD.

Study participants were randomized into one of three treatment groups, with 36 participants receiving 20 IU (international unit) of insulin daily, 38 receiving 40 IU of insulin daily, and 30 participants receiving placebo daily for four months. All treatments were administered using a nasal drug delivery device. The authors evaluated the effects of treatment on delayed story recall (how well participants could recall a story told to them immediately after, and after a short time lapse) and the Dementia Severity Rating Scale (DSRS) scores of participants.

Compared with participants in the placebo-controlled group, those receiving 20 IU of insulin daily showed improved delayed story recall, however no improvement was observed for participants receiving 40 IU of insulin. Also, compared with the placebo group, DSRS scores were preserved for both insulin treatment groups. Both insulin doses also appeared to preserve general cognition for younger participants as assessed by the Alzheimer Disease's Assessment Scale-cognitive subscale (ADAS-cog) score as well as functional abilities in adults with AD as assessed by scores on the Alzheimer's Disease Cooperative Study-activities of daily living (ADCS-ADL) scale. Conversely, participants with aMCI showed no change regardless of treatment assignment and participants in the placebo-controlled group showed a slight decline overall in function.

"In conclusion, the results of our pilot trial demonstrate that the administration of intranasal insulin stabilized or improved cognition, function and cerebral glucose metabolism for adults with aMCI or AD," the authors write. "Taken together, these results provide an impetus for future clinical trials of intranasal insulin therapy and for further mechanistic studies of insulin's role in the pathogenesis of AD."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Suzanne Craft; Laura D. Baker; Thomas J. Montine; Satoshi Minoshima; G. Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R. Plymate; Pattie S. Green; James Leverenz; Donna Cross; Brooke Gerton. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial. Archives of Neurology, 2011; DOI: 10.1001/archneurol.2011.233

Cite This Page:

JAMA and Archives Journals. "Study evaluates intranasal insulin therapy for adults with mild cognitive impairment or Alzheimer’s." ScienceDaily. ScienceDaily, 13 September 2011. <www.sciencedaily.com/releases/2011/09/110912164014.htm>.
JAMA and Archives Journals. (2011, September 13). Study evaluates intranasal insulin therapy for adults with mild cognitive impairment or Alzheimer’s. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2011/09/110912164014.htm
JAMA and Archives Journals. "Study evaluates intranasal insulin therapy for adults with mild cognitive impairment or Alzheimer’s." ScienceDaily. www.sciencedaily.com/releases/2011/09/110912164014.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins